CREXONT's launch exceeded expectations with high patient satisfaction and rapid adoption. Formulary access is at 30%, aiming for 50%. Amneal focuses on organic growth in affordable medicines and injectables, with plans for biosimilars.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay